Drug

Esketamine

Established medicine

ClassGlutamate [NMDA] receptor negative allosteric modulatorResearchOngoing clinical research

Also known as (-)-Ketamine, (S)-(-)-ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, (S)-ketamine+6 more

(-)-Ketamine, (S)-(-)-ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, (S)-ketamine, L-ketamine, S-(-)-Ketamine, S-ketamine, Spravato, s(+)ketamine, Esketamina.

RxNorm2119365 ChEMBLCHEMBL395091 ATCN06AX27 ATCN01AX14UNII50LFG02TXD

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Ketamine, Esketamine May Reduce Postoperative Delirium Risk

Industry2026-10-22Medscape Medical News

<![CDATA[Running a Sustainable Esketamine Treatment Center for TRD]]>

Industry2026-10-06Psychiatric Times

<![CDATA[Safety Monitoring and Treatment Continuation With Esketamine in TRD]]>

Industry2026-10-06Psychiatric Times

<![CDATA[Choosing Between Ketamine and Esketamine in TRD]]>

Industry2026-10-06Psychiatric Times

<![CDATA[Interventional Options for TRD: ECT, TMS, and Esketamine]]>

Industry2026-10-05Psychiatric Times

<![CDATA[Esketamine, Off-Label Ketamine, and the Regulatory Gap: A Conversation With Lisa Harding, MD]]>

Regulatory2026-10-03Regulatory news · Psychiatric Times

Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery: A Multi-Center Randomized Controlled Trial

Clinical trial2026-09-30Withdrawn · ClinicalTrials.gov

A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior

Clinical trial2026-09-25Results expected Q2 2031 · ClinicalTrials.gov

<![CDATA[Building Interventional Psychiatry Services: TMS, Esketamine, and What Comes Next]]>

Industry2026-09-22Psychiatric Times

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

Clinical trial2026-09-16Results expected Q4 2028 · ClinicalTrials.gov

Propofol, Dexmedetomidine, and Esketamine-Induced Unresponsive States: Alterations in Information Integration and Brain Networks

Clinical trial2026-08-31Primary completion · ClinicalTrials.gov

Efficacy of a Single Low Dose of Esketamine for Patients With Irritable Bowel Syndrome: Study Protocol for a Randomised Controlled Trial

Clinical trial2026-08-28Results expected Q4 2026 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Esketamine

Aliases & brands

(-)-Ketamine(S)-(-)-ketamine(S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone(S)-ketamineL-ketamineS-(-)-KetamineS-ketamineSpravatos(+)ketamineEsketamina

RxNorm CUI

2119365

ChEMBL ID

CHEMBL395091

ATC codes

N06AX27N01AX14

UNII

50LFG02TXD

Primary mechanism

Glutamate [NMDA] receptor negative allosteric modulator

Pharmacology & targets

7 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glutamate receptor ionotropic, NMDA 1

GRIN1 · Q05586